Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company dedicated to developing innovative therapies to restore, treat and prevent hearing loss, announces that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation the Company’s most advanced gene therapy program, OTOF-GT, a gene therapy planned for the treatment of hearing loss linked to the otoferlin gene.
Sensorion’s gene therapy product development program, OTOF-GT, aims to restore hearing to patients with otoferlin deficiency, one of the most common forms of congenital deafness